Berenberg Bank Keeps a Buy Rating on Qiagen NV (QGEN)

By Jason Carr

In a report issued on July 25, Scott Bardo from Berenberg Bank maintained a Buy rating on Qiagen NV (QGENResearch Report), with a price target of $40. The company’s shares closed yesterday at $38.29.

Bardo has an average return of 8.9% when recommending Qiagen NV.

According to TipRanks.com, Bardo is ranked #541 out of 5256 analysts.

Qiagen NV has an analyst consensus of Moderate Buy, with a price target consensus of $43.20, which is a 12.8% upside from current levels. In a report issued on July 25, Barclays also maintained a Buy rating on the stock with a $42 price target.

See today’s analyst top recommended stocks >>

Based on Qiagen NV’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $44.7 million. In comparison, last year the company had a net profit of $36.82 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services.